Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery

Infection Control and Hospital Epidemiology

Volumn 23, Issue 7, 2002, Pages 402-404

  Spelman, Denis ^a   Harrington, Glenys ^a   Russo, Phil ^a   Wesselingh, S ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUSTRALIA; CORONARY ARTERY BYPASS GRAFT; DRUG CHOICE; HEALTH CARE COST; HEART SURGERY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; SURGICAL INFECTION;

EID: 0036328985     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502074     Document Type: Article

References (10)

1. Antibiotic prophylaxis for cardiothoracic operations
2. CDC definitions of surgical site infection, 1992: A modification of CDC definitions of surgical site infections
3. Risk factors for surgical wound infection and bacteremia following coronary artery bypass surgery
4. The cost of surgical site infections following coronary artery bypass graft surgery
5. Comparative study of cefazolin, cefamandole and vancomycin for surgical prophylaxis in cardiac and vascular operations
6. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery
7. Rifampicin blood and tissue levels in patients undergoing cardiac valve surgery
8. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients